Relmada Therapeutics, Inc. financial data

Symbol
RLMD on Nasdaq
Location
2222 Ponce De Leon Blvd. 3 Rd Floor, Coral Gables, FL
State of incorporation
Nevada
Fiscal year end
December 31
Former names
CAMP NINE, INC. (to 7/14/2014)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 851 % -23%
Return On Equity -78.5 %
Return On Assets -95.8 % -11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.2M shares +0.25%
Common Stock, Shares, Outstanding 30.2M shares +0.25%
Entity Public Float 73M USD -87%
Common Stock, Value, Issued 30.2K USD +0.25%
Weighted Average Number of Shares Outstanding, Basic 30.2M shares +0.25%
Weighted Average Number of Shares Outstanding, Diluted 30.2M shares +0.25%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 49.2M USD -43.4%
General and Administrative Expense 42.1M USD -5.66%
Operating Income (Loss) -91.3M USD +30.6%
Nonoperating Income (Expense) 4.57M USD +73.4%
Net Income (Loss) Attributable to Parent -86.8M USD +32.7%
Earnings Per Share, Basic -2.88 USD/shares +32.7%
Earnings Per Share, Diluted -2.88 USD/shares +29.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.09M USD -85.6%
Other Assets, Current 256K USD
Assets, Current 71M USD -41.8%
Other Assets, Noncurrent 53.6K USD +55%
Assets 71M USD -41.8%
Accounts Payable, Current 4.17M USD -14%
Accrued Liabilities, Current 5.36M USD -8.32%
Liabilities, Current 9.54M USD -10.9%
Liabilities 12.4M USD +22.4%
Retained Earnings (Accumulated Deficit) -600M USD -16.9%
Stockholders' Equity Attributable to Parent 61.5M USD -44.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 166M USD +129%
Liabilities and Equity 71M USD -41.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13M USD +21%
Net Cash Provided by (Used in) Financing Activities 222K USD
Net Cash Provided by (Used in) Investing Activities 10.1M USD -74.9%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 30.2M shares +0.25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.5M USD +4686%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.09M USD -85.6%
Deferred Tax Assets, Valuation Allowance 110M USD -5.38%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.01 pure
Preferred Stock, Shares Authorized 200M shares +5614%
Additional Paid in Capital 662M USD +5.91%
Share-based Payment Arrangement, Expense 8.3M USD -26.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%